USANA Health Sciences share price today

USANA Health Sciences, Inc.'s share price was $14.33 at the close on 4 November 2026. That is 20.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $13 and $23, and at that close it sat 10% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 14 weeks running.

Over the last 1 year the share price moved −57% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

USANA Health Sciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

USANA Health Sciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

USANA Health Sciences, Inc. posted a net loss of $21.4 M in the Jul 2026 quarter. Full-year FY26 profit was $10.8 M. Over 4 years profit has grown −44.9% a year on average. That loss is 9.6% of the quarter's revenue. The same quarter a year earlier earned $9.7 M. 3 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Jul 2026 profit was −$21.4 M, −321.5% on a year earlier. For the full year, FY26 profit was $10.8 M (−74.4% on the year before).

Why profit moved: revenue changed −5.3% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −167.7% and revenue +0.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

USANA Health Sciences, Inc. reported $223 M of revenue in the Jul 2026 quarter, −5.3% on the same quarter a year earlier. Over 4 years it has grown −6.0% a year on average. The last full year, FY26, came in at $925 M. The last four reported quarters add to $913 M.

Revenue is everything the company billed its customers in the period.

FY26 revenue was $925 M, +8.3% on the year before.

Recent pace: the last four quarters grew +0.6% on average, against −6.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +1.6%, against +2.2% a year over the last 8 quarters (stabilising).

USANA Health Sciences, Inc.'s operating margin was 4.1% in the Jul 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Across 5 years it has been between 5.5% and 14.3%. The latest quarter is below every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −3.0 percentage points on the year while gross margin changed −0.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 132% of USANA Health Sciences, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $22.3 M of operating cash against $10.8 M of profit. After $13.8 M of spending on assets, $8.5 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

USANA Health Sciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $38.4 M on assets over the last 3 years. Averaged over those years that is 1.4% of FY26 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $38.4 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

USANA Health Sciences, Inc.'s P/E is 47.3×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −73.5% while the price moved −25.1%. The price did better than earnings, which pushed the multiple up within its own range.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

USANA Health Sciences, Inc.'s business is getting worse. Profit and EPS growth are shrinking: profit growth is −165.0% in the latest quarter, against −5.1% at its best in 12 quarters, with ROCE steady at 6.9%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

USANA Health Sciences, Inc. earned a ROE of 2% in FY26. Its return on capital used (ROIC) is 1.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 1.2% net margin and 1.25× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY26): a 1.2% net margin × 1.25× asset turnover × 1.27× leverage (assets divided by equity) ≈ 1.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 9.8% − 7.9% = +1.9 percentage points. The 7.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

The 9.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 3.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

USANA Health Sciences, Inc. has total debt of $14.0 M against shareholder equity of $595 M as of Apr 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.05 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

7.8% of USANA Health Sciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For USANA Health Sciences, Inc., the Z-score is 4.58. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 4.58 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: USANA Health Sciences, Inc. is not among the largest members shown in this industry comparison for Packaged Foods.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

USANA Health Sciences is the 35th largest of 39 Packaged Foods companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Lifeway Foods, Inc., CN Healthy Food Tech Group Corp. and Prenetics Global. Just below it: Oatly Group AB, BRC Inc. and Nature's Sunshine Products, Inc.

Packaged Foods companies close in size

32. Lifeway Foods, Inc. $337 million
33. CN Healthy Food Tech Group Corp. $288 million
34. Prenetics Global Limited $272 million
35. USANA Health Sciences, Inc. $265 million
36. Oatly Group AB $261 million
37. BRC Inc. $244 million
38. Nature's Sunshine Products, Inc. $226 million

All 39 Packaged Foods companies, largest first

Companies close in size in other industries

3205. Maui Land & Pineapple Company, Inc. $275 million · Real Estate Services
3206. Century Therapeutics, Inc. $275 million · Biotechnology
3207. USANA Health Sciences, Inc. $275 million
3208. Blend Labs, Inc. $274 million · Software - Application
3209. Prenetics Global Limited $274 million · Packaged Foods

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.